23Andme Holding Co (ME)

NASDAQ
4.65
-0.16(-3.33%)
After Hours
4.72
+0.07(+1.51%)
- Real-time Data
  • Volume:
    2,472,035
  • Bid/Ask:
    4.70/4.78
  • Day's Range:
    4.63 - 5.13

ME Overview

Prev. Close
4.81
Day's Range
4.63-5.13
Revenue
59.24M
Open
4.85
52 wk Range
4.63-18.14
EPS
-0.66
Volume
2,472,035
Market Cap
2.15B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
3,069,356
P/E Ratio
-
Beta
-
1-Year Change
-66.45%
Shares Outstanding
461,366,101
Next Earnings Date
Mar 02, 2022
What is your sentiment on 23Andme Holding Co?
or
Market is currently closed. Voting is open during market hours.

23Andme Holding Co Company Profile

23andMe Holding Co. operates as a consumer genetics and research company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize promising drugs. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. The company was founded in 2006 and is headquartered in Sunnyvale, California.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellSell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • 🚀🚀🚀
    1
    • 23andMe Agrees to Acquire Lemonaid Health. The purchase price is 400m, of which 25% cash and 75% in shares calculated on a fixed value of 8.82 per share. So 34m new shares to be issued.
      2
      • ME (T) 1 10.19
        0
        • $20 soon?
          1
          • What's the news boys?
            0
            • Why the surge?
              0
              • EMJ Capital founder and president Eric Jackson named it one of his stock picks on CNBC's "Closing Bell."
                0
                • thank you, looking into EMJ and Eric Jackson now.
                  0
              • up 13% AH? let's do it!
                0
                • This is the kind of stock you'll regret not having bought one day.
                  0
                  • ***stock ***company.
                    0
                    • This the kind of stock you buy at 5 dollar one day
                      7
                      • 2
                        2
                      • this is the type of stock you don't buy! talking from experience buddy. f&*$ branson!
                        0
                      • Rachit, just buy NGCA for Virgin Orbit :)
                        0
                    • Branson likes to tank his own stocks.. this will tank soon. prove me wrong Branson...
                      0
                      • thought 8 clicked reply..
                        0
                      • Stocks OptionsBranson was all in on his space program, and having cash liquidity problems. Probably sold many different stocks that he otherwise would have kept.
                        0
                      • he's just a scam
                        0
                    • I have some questions about the company. As far as I know, many people in the US have used the 23andme's DNA test products already but do they have any other ways to gather more users besides the subscription services and CEO speeches?
                      0
                      • I'm not sure. These forums aren't usually the best way to get reliable information. I'd use Bloomberg, WS Journal, Stansberry Newswire and other more objective sources. As a 23 & Me customer for several years and shareholder since last week price it $10 entry (adding each $0.25 drop lower), I know it offers an excellent product and expanding information services, has broad sample size in North America and few other parts of the world, but needs to expand users and sample size outside it core markets for more basic research, and I'm thinking it's heading in the right direction. I do consider it a biotech speculation, so smaller position size than less volatile sectors and asset types, but not nearly as speculative and risky as many biotechs that only have one or few products they're working on.
                        1
                      • They’re also doing a deep dive into Genome research with the ultimste goal of curing deseases.
                        0
                    • Global Biotech market expected to surpass 729 billion by 2025 https://www.prnewswire.com/news-releases/biotechnology-market-value-worth-729-billion-by-2025-global-market-insights-inc-300969541.html
                      0
                      • Moving to nasdaq on Thursday, June 17! Ticker symbol ME
                        1
                        • On which platform can i buy vgac stocks from Italy ?
                          0
                          • Degiro
                            0
                        • The extraordinary general meeting will be held on June 10th. Partecipation and vote are allowed to be done online, details on today's Sec form.
                          1
                          • VGAC (23andme to be) is a long term genomics investment. It will be added to ARKG.
                            0
                            • Richard Scam Branson
                              0
                              • agreed. he's a thief.
                                0
                            • What do you think - should we dump this or hold. Could use the $$$ to invest in something that is making money.
                              0
                              • We should be heariing some merger news soon. I't been 2 months since the announcement.
                                0
                                • yeah. and? stock still dropping after merger. Branson must be selling taking investors hard earned money.
                                  0
                              • We need some news so this thing will go back up!!!
                                0
                                • Still waiting!!! Think I'll bail out once it gets back to my buy price. Outlook not looking too great for this one!
                                  1
                                  • everybody thought 23andme was a big deal. it was one of a kind but their predicted earnings are disappointment
                                    0
                                    • oh yeah ? when is er?
                                      0
                                  • Already accumulated. Waiting!
                                    0
                                    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.